Delivering new horizons for heart health

Beyond statins

Esperion is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density, lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Many patients with elevated risk of heart disease are unable to benefit from statins, the current leading treatments, due to the side effects caused by these therapies: this is known as statin intolerance. Our lead product candidate, ETC-1002, is a first-in-class orally available small molecule designed to significantly lower elevated levels of LDL-C and improve other cardiometabolic risk markers — without the muscle-related side effects associated with statin use.

Clinical Studies

Esperion completed enrollment in ETC-1002-008, a Phase 2b clinical study of ETC-1002 that includes approximately 350 patients with hypercholesterolemia and a history of statin intolerance or statin tolerance. Top-line results from this study will be reported in early October 2014.


Meet Esperion

Our founder, executive chairman and chief scientific officer, Roger Newton, co-discovered the statin marketed as Lipitor® — the most prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history. Learn more about our management team’s track record of success.


Statin Intolerance

Despite the known efficacy of statins, approximately 5-20% of adults who experience muscle pain or weakness discontinue statin therapy because of muscle related adverse events: this is known as statin intolerance.